InTrack Investment Management Inc decreased its stake in shares of The Clorox Company (NYSE:CLX – Free Report) by 37.7% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,650 shares of the company’s stock after selling 1,000 shares during the period. InTrack Investment Management Inc’s holdings in Clorox were worth $253,000 as of its most recent filing with the SEC.
A number of other institutional investors have also made changes to their positions in CLX. Point72 Asset Management L.P. bought a new stake in shares of Clorox in the 4th quarter worth approximately $144,844,000. Norges Bank bought a new position in shares of Clorox during the fourth quarter worth about $128,382,000. Parsifal Capital Management LP acquired a new stake in shares of Clorox in the 4th quarter worth about $128,245,000. Confluence Investment Management LLC bought a new stake in Clorox in the 1st quarter valued at about $135,630,000. Finally, International Assets Investment Management LLC boosted its stake in Clorox by 17,658.5% during the 4th quarter. International Assets Investment Management LLC now owns 484,453 shares of the company’s stock valued at $69,078,000 after purchasing an additional 481,725 shares during the period. 78.53% of the stock is currently owned by institutional investors.
Clorox Stock Performance
Shares of NYSE CLX traded down $0.70 during mid-day trading on Tuesday, hitting $133.54. The company had a trading volume of 903,097 shares, compared to its average volume of 1,259,952. The Clorox Company has a 12 month low of $114.68 and a 12 month high of $169.14. The company has a debt-to-equity ratio of 9.73, a current ratio of 0.90 and a quick ratio of 0.53. The firm has a market cap of $16.58 billion, a P/E ratio of 69.19, a PEG ratio of 2.19 and a beta of 0.39. The business’s 50-day simple moving average is $136.74 and its 200-day simple moving average is $143.73.
Wall Street Analyst Weigh In
Several research analysts have recently issued reports on the stock. Evercore ISI lowered their target price on Clorox from $145.00 to $142.00 and set an “underperform” rating on the stock in a report on Wednesday, May 1st. UBS Group dropped their target price on shares of Clorox from $164.00 to $159.00 and set a “neutral” rating on the stock in a report on Wednesday, May 1st. BNP Paribas initiated coverage on shares of Clorox in a report on Monday, June 24th. They set an “underperform” rating and a $130.00 target price for the company. JPMorgan Chase & Co. dropped their price target on Clorox from $159.00 to $158.00 and set a “neutral” rating on the stock in a report on Wednesday, May 1st. Finally, Citigroup reduced their price objective on Clorox from $155.00 to $150.00 and set a “neutral” rating for the company in a research note on Wednesday, May 1st. Five analysts have rated the stock with a sell rating and fourteen have given a hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $145.33.
Read Our Latest Research Report on Clorox
Clorox Company Profile
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.
Recommended Stories
- Five stocks we like better than Clorox
- Following Congress Stock Trades
- RXO Shares Surge Following New Acquisition Deal
- What Are Dividend Achievers? An Introduction
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.